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Abstract
Aim—To investigate whether serum levels
of soluble intercellular adhesion molecule
1 (sICAM-1) can serve as a marker of the
presence of systemic disease in intermedi-
ate uveitis.
Methods—In a multicentre study
sICAM-1 serum levels were measured in
61 patients with idiopathic intermediate
uveitis, controls included 56 uveitis pa-
tients with a systemic disease (26 sarcoid
associated uveitis and 30 HLA-B27 posi-
tive acute anterior uveitis), 58 uveitis
patients without systemic disease (30
toxoplasma chorioretinitis and 28 Fuchs’
hetrochromic cyclitis), and 21 normal
controls. The clinical records of the pa-
tients with intermediate uveitis were ana-
lysed for disease characteristics at the
time of blood sampling and for a relation
with the development of a systemic dis-
ease after a mean follow up of 4.5 years.
Results—Increased serum levels of
sICAM-1 were found in 34 out of 61
patients with intermediate uveitis and
were significantly diVerent when com-
pared with toxoplasmosis, Fuchs’ cyclitis,
and healthy controls (p<0.001). Elevated
sICAM-1 levels were also found in 18 out
of 26 patients with sarcoid uveitis and in 11
out of 30 patients with HLA-B27 associ-
ated anterior uveitis. Raised sICAM-1 lev-
els in the intermediate uveitis group were
significantly associated with active ocular
disease (p<0.01) and the presence of vitre-
ous exudates (p<0.05). Increased levels of
sICAM-1 correlated with interleukin 8
levels (IL-8) (tested in a previous study in
the same group of intermediate uveitis
patients) in patients with active systemic
involvement. Follow up of the patients
showed that an established or suspected
systemic disease was found more often in
the 21 intermediate uveitis patients with
increased sICAM-1 and IL-8 levels com-
pared with the other 40 patients with
intermediate uveitis (p<0.01).
Conclusions—The measurement of both
sICAM-1 and IL-8 can be used as a
marker for ocular disease activity and for
a predisposition of developing an associ-
ated systemic disease in intermediate
uveitis patients.
(Br J Ophthalmol 1999;83:847–851)
Intermediate uveitis accounts for approxi-
mately 8–16% of uveitis cases.1–3 The diagnosis
of intermediate uveitis is made when ocular
inflammation predominantly involves the vitre-
ous and peripheral retina.1 4 The disease tends
to mostly aVect young adults although it can
also be diagnosed later in life. The aetiology of
intermediate uveitis is still unknown. The
association of intermediate uveitis with sys-
temic diseases such as multiple sclerosis and
sarcoidosis suggests that at least some cases of
this heterogeneous ocular disorder are autoim-
mune in nature.5–7 In cases of idiopathic inter-
mediate uveitis it is possible that an underlying
systemic disease may not yet be obvious.
In an earlier study we found increased levels
of interleukin 8 (IL-8) in patients with active
intermediate uveitis, a phenomenon which
suggests a systemic involvement.8 Other im-
mune mediators such as intercellular adhesion
molecule 1 (ICAM-1) were also reported to be
upregulated in retinal inflammatory diseases.9
ICAM-1 is an adhesion molecule belonging to
the immunoglobulin superfamily that is ex-
pressed on cells of multiple lineage at sites of
inflammation10–14 It is important for leucocyte
adhesion, transendothelial migration, and cell-
cell interactions in immune responses.15 It has
been suggested that ICAM-1 is an early marker
of immune activation and response. A circulat-
ing soluble form of ICAM-1 (sICAM-1) has
been detected in human serum.16 17 High levels
of sICAM-1 have been reported in inflamma-
tory and autoimmune diseases such as
rheumatoid arthritis, spondylarthropathies,
sarcoidosis, and multiple sclerosis.18–23 Further-
more, it has been suggested that high levels of
sICAM-1 correlate well with disease activity in
multiple sclerosis,22 23 sarcoidosis,20 21 and also
in patients with retinal vasculitis.24
Whether sICAM-1 can also be useful as an
indicator for the presence of systemic disease in
intraocular inflammation is not yet clear and
was the main objective of this study.
Patients and methods
Sixty one patients with intermediate uveitis
who visited the uveitis clinics of the Academic
Hospital of the Free University of Amsterdam
and the Academic Hospital of Utrecht in the
period between 1981 and 1996 were included
in this study (this group of intermediate uveitis
patients was also included in our previous
study for IL-88). All patients underwent a com-
plete examination for uveitis,25 a complete
ophthalmological examination was performed
in all cases, and their personal and family
histories were reviewed. The patients were
especially asked for arthralgias, skin rash,
gastrointestinal symptoms, and neurological
symptoms. Blood samples for uveitis screening
(erythrocyte sedimentation rate, C reactive
protein, red and white blood cell counts,
Br J Ophthalmol 1999;83:847–851 847
Department
Ophthalmo-
Immunology,
Netherlands
Ophthalmic Research
Institute, Amsterdam
A-M Klok
L Luyendijk
A Kijlstra
Department of
Ophthalmology, Free
University,
Amsterdam
A-M Klok
M J W Zaal
Department of
Ophthalmology,
University of
Amsterdam,
Amsterdam
A-M Klok
A Kijlstra
Department of
Ophthalmology,
University of Utrecht,
Utrecht
A Rothova
Correspondence to:
Anne-Marie Klok,
Department
Ophthalmo-Immunology,
Netherlands Ophthalmic
Research Institute,
Amsterdam, PO Box 12141,
1100 AC Amsterdam,
Netherlands.
Accepted for publication
12 January 1999
 group.bmj.com on December 27, 2011 - Published by bjo.bmj.comDownloaded from 
angiotensin converting enzyme, syphilis serol-
ogy, and borrelia serology) were obtained by
venepuncture and sera were aliquoted and
stored frozen (−20°C) for future studies. Chest
radiography and fluorescein angiography was
performed in all patients. Selected patients
(depending on history, character, and activity
of their ocular disease as well as the outcome of
the laboratory and radiographic screening pro-
cedures) underwent special tests and diagnos-
tic procedures. These tests included computed
tomography (CT) of chest or brain, gallium-67
whole body scintigraphy, and Mantoux testing.
No evidence of systemic or infectious disease
was found at entry to the study in any of the
patients after uveitis screening. During follow
up, patients were asked for new ocular or
systemic symptoms and complete ophthalmic
examinations were performed at each visit.
Screening for sarcoidosis (angiotensin convert-
ing enzyme and chest radiography) was re-
peated regularly. When patients had symptoms
of extraocular diseases they were referred to
other medical specialists (pulmonologist, rheu-
matologist, neurologist, dermatologist) for fur-
ther evaluation.
In all patients with intermediate uveitis the
intraocular inflammation was predominantly
localised in the vitreous, pars plana, or periph-
eral retina. At the time of venepuncture the
presence of cystoid macular oedema (CMO),
vitreous exudates or snowbank formation,
papillitis, and periphlebitis (based on fluores-
cein angiography) were scored. Disease activity
was divided into active or smouldering. Active
intermediate uveitis was defined as an exacer-
bation of the disease with marked inflamma-
tory reaction with cells and debris in the vitre-
ous (Hogan and Kimura, grade 2–4).25 In
smouldering disease there was no exacerbation
but a minimal to moderate cellular infiltration
within the vitreous was still present.
Most patients with intermediate uveitis were
between 20 and 40 (n=48, 79%) years of age at
the onset of ocular disease, five were younger
than 20, and 18 were older than 40. Forty three
patients were female and 18 were male. Most
of the intermediate uveitis patients were not
treated or were taking topical corticosteroid
treatment at first presentation to one of our
clinics. Only five patients were taking systemic
immunosuppression. Mean follow up after
venepuncture of the intermediate uveitis pa-
tients was 4.5 years with a range of 6 months to
15 years.
Serum samples of 56 uveitis controls with an
associated systemic disease and active ocular
disease (26 patients with sarcoid anterior uvei-
tis and 30 HLA-B27 positive acute anterior
uveitis), 58 uveitis controls without systemic
disease (30 toxoplasmic chorioretinitis and 28
Fuchs’ heterochromic cyclitis), and 21 healthy
controls were collected in the same period as
the intermediate uveitis group and stored
under similar conditions. In all patients a
specific diagnosis of uveitis was made accord-
ing to the criteria of the International Uveitis
Study Group.26 Serum levels of sICAM-1 were
detected using a commercially available en-
zyme linked immunosorbent assay (ELISA,
human soluble ICAM-1 immunoassay, R&D
Systems) according to the manufacturer’s
instructions. The concentration of sICAM-1 in
samples was calculated by comparing the
obtained ELISA reading with a standard curve
generated from standards of known concentra-
tion supplied with the kit. Adsorbance was
determined at 450 nm. A value of 300 ng/ml
was considered as elevated. This value was cal-
culated by taking the mean plus two times the
standard deviation of our controls. This value
is in accordance to the upper limit for healthy
individuals as provided by the manufacturer.
Statistical analysis of the data was performed
using Mann-Whitney U test and ÷2 test.
Results
Elevated sICAM-1 levels (>300 ng/ml) were
found in 34 of the 61 patients with intermedi-
ate uveitis (56%) (Table 1, Fig 1). sICAM-1
levels in intermediate uveitis were significantly
diVerent when compared with toxoplasmosis,
Table 1 Elevated sICAM-1 levels (>300 ng/ml) in serum
of uveitis patients
Diagnosis No/total %
Median
(ng/ml)
Range
(ng/ml)
Intermediate uveitis* 34/61 56 337 181–684
Sarcoidosis 18/26 69 504 146–1585
HLA-B27 AAU 11/30 37 298 175–472
Toxoplasmosis 7/30 23 265 145–439
Fuchs’ cyclitis 1/28 4 238 177–316
Controls 0/21 — 203 98–287
AAU = acute anterior uveitis.
*sICAM-1 levels in intermediate uveitis were significantly
diVerent compared with toxoplasmosis, Fuchs’ cyclitis, and
controls (p<0.001, Mann–Whitney U test).
Figure 1 sICAM-1 levels in serum from intermediate
uveitis patients, uveitis controls, and normal controls. The
line represents the value above which the assay is considered
positive. AAU= acute anterior uveitis.
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Table 2 sICAM-1 and disease activity in intermediate
uveitis
sICAM-1 pos*
(n=34)
sICAM-1 neg
(n=27) p Value
Active 27 12 <0.01
Smouldering 7 15
*sICAM-1 level above 300 ng/ml.
Statistical analysis was performed using the ÷2 test.
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Fuchs’ heterochromic cyclitis, and normal
controls (p<0.001). High levels of sICAM-1
were also seen in 18 of the 26 patients with sar-
coidosis (69%) and 11 of the 30 HLA-B27
acute anterior uveitis patients (37%). Of the
intermediate uveitis patients with active ocular
disease (n=39), 27 (70%) had elevated circu-
lating sICAM-1 levels compared with seven
out of 22 patients with smouldering intraocular
inflammation (p<0.01) (Table 2). When ana-
lysing the relation between sICAM-1 and ocu-
lar characteristics, only vitreous exudates were
found more often in patients with elevated
sICAM-1 compared with patients with normal
sICAM-1 levels (p<0.05) (Table 3). The pres-
ence of CMO, papillitis, and periphlebitis did
not significantly diVer between patients with
elevated and normal sICAM-1 levels. Papillitis
was seen in seven patients of whom six had
elevated sICAM-1 levels. Owing to the small
numbers this finding did however not reach
statistical significance. No association was
observed between serum ICAM-1 levels and
age, sex of patients, or systemic corticosteroid
treatment of ocular disease.
In our previous study high IL-8 levels (>20
pg/ml) were found in 27 of these 61 patients
with intermediate uveitis. Raised IL-8 levels
were significantly associated with active disease
(p<0.001) and the presence of vitreous exu-
dates (p<0.001), papillitis, and periphlebitis
(p<0.01).8 Raised sICAM-1 or IL-8 are found
in intermediate uveitis, a finding that remains
significant even after correction of the p value
for the number of analysis performed.
Analysis of the levels of sICAM-1 and IL-8
in the 61 patients with intermediate uveitis
showed that all patients with increased
sICAM-1 and increased IL-8 had active
disease (Fig 2).
At the end of the study (mean follow up of
4.5 years after blood sampling) a systemic dis-
ease was found in five patients and was
suspected in eight patients (Table 4). Four
patients developed multiple sclerosis; two had
high levels of sICAM-1 and IL-8 and both had
active ocular disease; the other two patients
who developed multiple sclerosis had smoul-
dering ocular disease with low sICAM-1 and
IL-8 levels, one of these was on systemic
immunosuppression. In one patient a diagnosis
of sarcoidosis was made 2 years after the entry
into the study; this patient had active disease
with high levels of sICAM-1 and IL-8. Three
patients developed optic neuritis and other
neurological symptoms and were suspected of
having multiple sclerosis but have not yet
fulfilled the Poser criteria for a definite MS27:
all had active ocular disease. Two of them were
sICAM-1 positive and all were IL-8 positive. In
five additional patients serum angiotensin con-
verting enzyme levels increased from normal to
high levels and/or had chest radiographic or
gallium-67 scintigraphic patterns typical of
sarcoidosis without, however, confirmation of
the diagnosis by histological examination of
biopsy specimens. These were suspected of
having sarcoidosis; four had active disease with
high sICAM-1 and IL-8 levels, one patient
treated with systemic steroids had smouldering
disease with low sICAM-1 and IL-8 levels. An
established or suspected systemic disease was
significantly more often found in the 21
patients with intermediate uveitis with in-
creased levels of both sICAM-1 and IL-8 com-
pared with the other 40 patients with interme-
diate uveitis (p<0.001). No statistical
diVerence was found in frequency of systemic
disease when the group of patients with
elevated sICAM-1 and elevated IL-8 was com-
pared with patients with elevated sICAM-1
and normal IL-8 levels, with patients with nor-
mal sICAM-1 and elevated IL-8 levels, or with
the group of intermediate uveitis patients with
normal sICAM-1 and normal IL-8 levels.
Discussion
In this study we found raised levels of
sICAM-1 in the serum of 56% of patients with
intermediate uveitis. Increased levels of
sICAM-1 were significantly related to in-
traocular inflammation. Increased levels of
Table 3 sICAM-1 and clinical aspects of intermediate
uveitis
Elevated
sICAM-1*
(n=34)
Normal
sICAM-1
(n=27) p Value
CMO† 14 7 ns
Vitreous exudates 24 12 <0.05
Papillitis 6 1 ns
Periphlebitis 8 6 ns
*sICAM-1 level above 300 ng/ml.
†Cystoid macular oedema.
Statistical analysis was performed using the ÷2 test.
Figure 2 sICAM-1 levels and IL-8 levels in serum from
patients with intermediate uveitis. The broken lines
represent the value above which the tests are considered
positive. The patients with increased sICAM-1 and
increased IL-8 had active disease.
10 000
1000
100
10
1
700600400 500
ICAM-1 (ng/ml)
Il-
8 
(p
g
/m
l)
3002000 100
Active disease
Smouldering 
disease
Table 4 Relation of sICAM-1 levels and IL-8 levels to the presence of systemic disease at
the end of the study in patients with intermediate uveitis
sICAM-1 ↑
IL-8 ↑ (21)
sICAM-1 ↑
IL-8 n (13)
sICAM-1 n
IL-8 ↑ (8)
sICAM-1 n
IL-8 n (19)
Multiple sclerosis 2 — — 2
Sarcoidosis 1 — — —
Multiple sclerosis suspect 2 — 1 —
Sarcoidosis suspect 4 — — 1
n = normal levels; ↑ = elevated levels.
An established or suspected systemic disease was significantly more found in the 21 patients with
elevated sICAM-1 and IL-8 compared with the other 40 intermediate uveitis patients (p<0.01, ÷2
test).
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sICAM-1 were also correlated with the pres-
ence of increased IL-8 levels in patients with
active intermediate uveitis. These findings sug-
gest that a systemic inflammatory reaction may
have a role in patients with intermediate
uveitis.
ICAM-1 seems to have a role in a variety of
cellular interactions involved in inflammatory
and immunological responses.16 It is expressed
on various cell types, is upregulated by
cytokines, and plays an important part in
leucocyte transendothelial migration and the
cell-cell contact.10–15 ICAM-1 was reported to
be expressed on endothelial cells of retinal and
choroidal blood vessels and the retinal pigment
epithelium in uveitic eyes.9
A soluble form of ICAM-1 has been
detected at increased concentrations in pa-
tients with inflammatory and autoimmune dis-
eases such as rheumatoid arthritis, spondylar-
thropathies, sarcoidosis, and multiple
sclerosis.18–23 High levels of sICAM-1 corre-
lated with clinical active disease or enhancing
lesions on magnetic resonance imaging in
patients with multiple sclerosis and were also
correlated with CSF pleocytosis, TNFá levels,
and blood-brain barrier damage.22 23 These
findings raise the possibility that circulating
ICAM-1 serves as a marker of acute inflamma-
tory events in multiple sclerosis. Increased
sICAM-1 levels were also correlated with
disease activity in patients with pulmonary
sarcoidosis.20 21
Raised circulating ICAM-1 levels have been
reported earlier in intermediate uveitis, sarcoid
associated uveitis, and retinal vasculitis.24 28 29
The first study reported by Arocker-Mettinger
et al 28 did not detect a relation with intraocular
inflammatory activity. Our findings are in
agreement with later studies of Palmer et al 24
and Zaman et al,29 who also found a relation
between ocular disease activity and sICAM-1
levels. We did not find a relation between
sICAM-1 and manifest periphlebitis noted
previously in patients with retinal vasculitis,
possibly because the number of patients with
intermediate uveitis with periphlebitis in our
study was quite low.
Furthermore, we found high levels of
sICAM-1 in patients with uveitis and other
systemic diseases (sarcoid associated uveitis
and HLA-B27 positive acute anterior uveitis).
This finding may indicate that idiopathic inter-
mediate uveitis is not an isolated eye disease
but is probably the first manifestation of an
otherwise subclinical systemic disease.
Evidence for a systemic immune response in
idiopathic uveitis patients has been found pre-
viously. Activated T cells were found in the
peripheral blood of patients with idiopathic
uveitis.30 Increased levels of sIL-2R were found
in patients with retinal vasculitis and systemic
inflammatory diseases,31 and in patients with
Fuchs’ heterochromic cyclitis and juvenile
chronic arthritis.32 These investigators did not
find elevated levels of sIL-2R in patients with
intermediate uveitis and sIL-2R was therefore
not considered to be a useful predictor in
intermediate uveitis.32
A major problem in the management of
intermediate uveitis is still the fact that the cur-
rently available laboratory tests cannot predict
the course and prognosis of ocular disease nor
identify an underlying systemic disease.There-
fore the introduction of new serological tests is
necessary.33 We have already described that
increased levels of IL-8 were associated with
active ocular disease in patients with interme-
diate uveitis and that this was not related to an
acute phase reaction because C reactive
protein levels were not raised.
At the end of the present study a relation
with systemic disease was suspected in 13
(21%) of the patients with intermediate uveitis.
A definite systemic disease was found in five
patients and eight patients had incomplete evi-
dence of associated systemic disease. Nine of
these patients were sICAM-1 and 10 were IL-8
positive at entry of the study; furthermore all
patients who were sICAM-1 positive also had
high levels of IL-8. None of the controls was
sICAM-1 positive, but five out of 29 controls
were positive in the IL-8 study, which indicates
that the measurement of sICAM-1 is probably
more specific than the measurement of IL-8.
In summary, this study shows that elevated
sICAM-1 levels are associated with ocular dis-
ease activity and that elevated levels of both
sICAM-1 and IL-8 seem to predispose to a
later development of an associated systemic
disease in patients with intermediate uveitis.
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